PREVYMIS®

Hold Company

MERCK SHARP DOHME

Learn More

Dosage and Administration

SOLUTION;INTRAVENOUS

Specification

240MG/12ML (20MG/ML); 480MG/24ML (20MG/ML)

Indication

PREVYMIS® is suitable for CMV prophylaxis in hematopoietic stem cell transplant (HSCT) recipients and CMV prophylaxis in kidney transplant recipients.

Use

Instructions for Use

API

LETERMOVIR

API Structure

We Supply

LETERMOVIR

Note:

In-house Standard
Facility GMP
Product GMP

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
10603384	2033/2/28
8513255	2024/5/22
RE46791	2024/5/22
7196086	2024/5/22

API Patent

Patent No	Expiration Date
8513255	2024/5/22
RE46791	2024/5/22
7196086	2024/5/22

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.